Company intelligence / Profile preview

Tachyon Therapeutics

Houston, Texas, United Statestachyontx.com ↗

Ownership: Private
Employees: ~1
Development stage: Other

Overview

Tachyon Therapeutics has initiated a Phase 1 clinical trial for its lead candidate TACH101, a first-in-class small molecule inhibitor of KDM4 histone demethylase, targeting patients with advanced or metastatic solid tumors. The company is also advancing additional oncology drug candidates targeting novel mechanisms of tumorigenesis. No active trials are currently listed on ClinicalTrials.gov as of the latest available data.

Therapeutic areas: Oncology
Modalities: Small molecules
Industry: Biotech

Drug pipeline

1 asset

zavondemstat

Partnerships

Exclusive license from Celgene Quanticel Research, Inc. (now Bristol Myers Squibb) for small molecule inhibitors of KDM4 including TACH101

Beyond the preview

Go deeper on Tachyon Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Tachyon Therapeutics.